Granulocyte Colony-Stimulating Factor After Intensive Consolidation Chemotherapy in Acute Myeloid Leukemia: Results of a Randomized Trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques

Harousseau, Jean‐Luc; Witz, Brigitte; Lioure, Bruno; Hunault, Mathilde; Desablens, B; Delain, Martine; Guilhot, Joëlle; Prise, P. Y. Le; Abgrall, Jean-François; Deconinck, Eric; Guyotat, Denis; Vilque, Jean-Pierre; Casassus, Philippe; Tournilhac, O.; Audhuy, B.; Solary, Éric

doi:10.1200/jco.2000.18.4.780

Cited by 82 publications

(72 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with severe neutropenia (Ͻ100 granulocytes/ mm 3 ) are at greatest risk (9,10), and the mortality rate for patients developing pneumonia in this setting can be as high as 67% (4). With the advent of stem cell transplantation and the use of colonystimulating factors, the duration of neutropenia post-BMT has been significantly shortened (11)(12)(13)(14)(15). Despite this, immunodeficiency can persist, and patients remain at increased risk for pulmonary infections.…”

Section: Defective Phagocytosis and Clearance Of Pseudomonas Aeruginomentioning

confidence: 99%

Defective Phagocytosis and Clearance of Pseudomonas aeruginosa in the Lung Following Bone Marrow Transplantation

Ojielo

Cooke²,

Mancuso

et al. 2003

The Journal of Immunology

128

View full text Add to dashboard Cite

Bone marrow transplantation (BMT) is an important therapeutic option for a variety of malignant and nonmalignant disorders. Unfortunately, BMT recipients are at increased risk of infection, and in particular, pulmonary complications occur frequently. Although the risk of infection is greatest during the neutropenic period immediately following transplant, patients are still vulnerable to pulmonary infections even after neutrophil engraftment. We evaluated the risk of infection in this postengraftment period by using a well-established mouse BMT model. Seven days after syngeneic BMT, B6D2F1 mice are no longer neutropenic, and by 3 wk, they demonstrate complete reconstitution of the peripheral blood. However, these mice remain more susceptible throughout 8 wk to infection after intratracheal administration of Pseudomonas aeruginosa; increased mortality in the P. aeruginosa-infected BMT mice correlates with increased bacterial burden in the lungs as well as increased systemic dissemination. This heightened susceptibility to infection was not secondary to a defect in inflammatory cell recruitment to the lung. The inability to clear P. aeruginosa in the lung correlated with reduced phagocytosis of the bacteria by alveolar macrophages (AMs), but not neutrophils, decreased production of TNF-α by AMs, and decreased levels of TNF-α and IFN-γ in the bronchoalveolar lavage fluid following infection. Expression of the β2 integrins CD11a and CD11c was reduced on AMs from BMT mice compared with wild-type mice. Thus, despite restoration of peripheral blood count, phagocytic defects in the AMs of BMT mice persist and may contribute to the increased risk of infection seen in the postengraftment period.

show abstract

Section: Defective Phagocytosis and Clearance Of Pseudomonas Aeruginomentioning

confidence: 99%

Defective Phagocytosis and Clearance of Pseudomonas aeruginosa in the Lung Following Bone Marrow Transplantation

Ojielo

Cooke²,

Mancuso

et al. 2003

The Journal of Immunology

128

View full text Add to dashboard Cite

show abstract

“…Consequently, randomized trials have analyzed whether the use of myeloid growth factors can reduce the duration of chemotherapyinduced neutropenia in AML patients without compromising antileukemic treatment. However, no consistent detrimental effects on survival have been reported with myeloid growth factors given to promote hematologic recovery following induction chemotherapy or after consolidation chemotherapy [10][11][12][13]. In contrast, the use of myeloid growth factors in AML patients to enhance hematologic recovery after HDCT with ASCT has not been similarly studied.…”

Section: Introductionmentioning

confidence: 99%

“…Thus, shortening the duration of neutropenia with granulocytecolony stimulating factor (G-CSF) after ASCT is expected to reduce infectious complications [9]. In fact, G-CSF given to support hematologic recovery following induction chemotherapy in AML patients has been shown to reduce the duration of neutropenia, the number of febrile episodes, the duration of hospitalization and the requirement for parenteral antibiotics [10][11][12][13]. In contrast, it is of no benefit if given together with chemotherapy as a priming strategy to improve survival rates [14].…”

Section: Introductionmentioning

confidence: 99%

Revisiting G-CSF Support for Hematologic Recovery after Autologous Transplantation in AML Patients

Oberson¹,

Novak²,

Taleghani³

et al. 2017

Ann Hematol Oncol

View full text Add to dashboard Cite

“…G-CSF therapy has considerably improved the safety of myelosuppressive chemotherapy, most notably in patients with lymphoma, and a decrease in the treatment-related mortality, higher complete remission rates, and longer diseasefree survival times have been reported in these patients (16,17,37). In addition to shortening the duration of neutropenia and hospitalization, G-CSF reduces the incidence of infections in patients with lymphoma (18,26,28,34). Although G-CSF generally has few side effects, some studies have indicated that G-CSF can exacerbate the lung toxicity caused by pneumotoxic agents (4,19,32) and can cause harmful lung effects even in the absence of known pneumotoxic drugs (4).…”

Section: Introductionmentioning

confidence: 99%

Effects of Granulocyte Colony-Stimulating Factor (G-CSF) on Bleomycin-Induced Lung Injury of Varying Severity

Adachi¹,

Suzuki²,

Sugimoto³

et al. 2003

Toxicol Pathol

View full text Add to dashboard Cite

We evaluated the effects of granulocyte colony-stimulating factor (G-CSF) on bleomycin (BLM)-induced lung injury that developed diffuse alveolar damage and subsequent pulmonary fibrosis (PF) of varying severity. G-CSF (100 µg/kg/day) was administered subcutaneously to BLM (0.2, 20, 2,000 µg)-treated or -untreated rats for 3 or 14 days. In the BLM 0.2 µg group, slight alveolar mononuclear cell infiltration was observed, although PF was not noted. In the BLM 20-µg and 2,000-µg groups, diffuse alveolar damage along with neutrophil infiltration and subsequent PF were observed. In the saline + G-CSF group and BLM 0.2 µg + G-CSF group, a marked increase in the number of alkaline phosphatase (ALP)-positive neutrophils was noted in the alveolar capillaries, although there was neither neutrophil infiltration in alveoli nor exacerbation of lung injury. In the BLM 20 µg + G-CSF and BLM 2,000 µg + G-CSF groups, an exacerbation of lung injury along with an increase in the number of ALP-positive neutrophils in the alveoli was observed. These results indicate that the administration of G-CSF to rats with slight lung injury bearing no PF does not exacerbate the lung injury. The exacerbating effects of G-CSF seem to be associated not only with the marked infiltration of activated neutrophils but also with the severity of underlying lung injury.

show abstract

Granulocyte Colony-Stimulating Factor After Intensive Consolidation Chemotherapy in Acute Myeloid Leukemia: Results of a Randomized Trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques

Abstract: G-CSF should be administered routinely after ICC to reduce the duration of neutropenia and hospitalization. However, G-CSF did not seem to significantly increase the feasibility of this two-course program or modify overall outcome.

Cited by 82 publications

References 25 publications

Defective Phagocytosis and Clearance of Pseudomonas aeruginosa in the Lung Following Bone Marrow Transplantation

Defective Phagocytosis and Clearance of Pseudomonas aeruginosa in the Lung Following Bone Marrow Transplantation

Revisiting G-CSF Support for Hematologic Recovery after Autologous Transplantation in AML Patients

Effects of Granulocyte Colony-Stimulating Factor (G-CSF) on Bleomycin-Induced Lung Injury of Varying Severity

Contact Info

Product

Resources

About